Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital, and Bio Supplies – develop, produce, and market innovative solutions and services in more than 100 countries.
As pioneers in the field of plasma science, the Bioscience Division is one of the largest plasma companies, with a growing network of centers worldwide. We develop this plasma into essential medicines used to treat chronic, rare, and, at times, life-threatening conditions. To ensure a safe and consistent source of plasma-derived medicines worldwide, we have a vertically integrated production process, from plasma collection through fractionation and purification, at our facilities in Spain and the United States.
Key essential plasma-derived products include immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and specialty hyperimmune globulins.
Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership in the industry.
For more information, please visit grifols.com